To evaluate the prognostic utility of combining PRRS with clinicopathological parameters, we constructed a nomogram based on WHO grade, age, 1p/19q codeletion status, MGMT promoter methylation status, and PRRS to predict the 1-, 3-, and 5-year survival rates of glioma patients (Figure 7C). The gene discussed is MGMT; the disease is central nervous system cancer.